$LQDA

Kaseta Michael sold $1.5M of LQDA

Kaseta Michael (CFO and COO) sold 20,430 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52, $1.46M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kaseta Michael
Published Jul 15, 2026, 12:08 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest fact is the CFO/COO’s open-market sale of 20,430 shares at $71.39 to $71.52, executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to change valuation absent accompanying fundamental news.

03

What to watch

The article does not provide context on total insider holdings, prior sale cadence, or whether other insiders also sold/bought around the same period.

Relevance 5/10Novelty 3/10Timing: after-hours/next-session context from a Form 4 filed 2026-07-14 for trades dated 2026-07-13

Background

The article is a SEC Form 4 insider transaction disclosure for Liquidia Corp (LQDA).

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia CFO and COO Kaseta Michael sold 20,430 shares in open-market trades at about $71.51 on 2026-07-13 under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 pre-arranged plan, which typically reduces the signal of new negative information.

Market effects

No clear sector read-through; this is company-specific insider selling without operational or guidance changes.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or planned liquidity needs, especially when executed under a 10b5-1 plan.

Key entities

  • Liquidia Corp

    Company whose insider transaction is disclosed on Form 4.

  • Kaseta Michael

    CFO and COO who sold shares in open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient